Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30967620

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Leukemia
Publication date
2019 Nov
First author
Pollyea DA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Pollyea DA
      type
      Author
    2. name
      Tallman MS
      type
      Author
    3. name
      de Botton S
      type
      Author
    4. name
      Kantarjian HM
      type
      Author
    5. name
      Collins R
      type
      Author
    6. name
      Stein AS
      type
      Author
    7. name
      Frattini MG
      type
      Author
    8. name
      Xu Q
      type
      Author
    9. name
      Tosolini A
      type
      Author
    10. name
      See WL
      type
      Author
    11. name
      MacBeth KJ
      type
      Author
    12. name
      Agresta SV
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Pollyea DA
      type
      Author
    2. name
      Tallman MS
      type
      Author
    3. name
      de Botton S
      type
      Author
    4. name
      Kantarjian HM
      type
      Author
    5. name
      Collins R
      type
      Author
    6. name
      Stein AS
      type
      Author
    7. name
      Frattini MG
      type
      Author
    8. name
      Xu Q
      type
      Author
    9. name
      Tosolini A
      type
      Author
    10. name
      See WL
      type
      Author
    11. name
      MacBeth KJ
      type
      Author
    12. name
      Agresta SV
      type
      Author
    bibliography ids
    1. nci-bib-d462c41b181688522c238637
    book metadata
    content sha256
    62c0ee301d0f644ca53bc537ae5031964f398029b13a1994a0a908fc4d86d58f
    document type
    citation
    dois
    1. 10.1038/s41375-019-0472-2
    electronic publication date
    display
    2019 Apr 9
    precision
    day
    year
    2019
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:30967620
    immutable id
    pubmed:30967620@62c0ee301d0f644ca53bc537ae5031964f398029b13a1994a0a908fc4d86d58f
    journal
    abbreviation
    Leukemia
    issn electronic
    1476-5551
    issn print
    0887-6924
    issue
    11
    name
    Leukemia
    nlm unique id
    8704895
    pages
    2575-2584
    volume
    33
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      30967620
      provenance
      batch id
      e808962322f3afebc564
      provider
      NCBI PubMed ESummary
      record sha256
      4528e9c827e3f6f9f10ee5628155bec165456cc762348a51c1ef9b092bda5aad
      response sha256
      3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
      retrieved at
      2026-09-09T23:47:41.002093+00:00
      publication date
      display
      2019 Nov
      precision
      month
      year
      2019
      publication types
      1. Clinical Trial, Phase I
      2. Clinical Trial, Phase II
      3. Journal Article
      4. Multicenter Study
      5. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/30967620/
      title
      Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

      Preserved source evidence · Not medical advice